Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B

摘要: Background In a previous randomized trial, AML HD98B, we showed that administration of all -trans retinoic acid in addition to intensive chemotherapy improved the outcome older patients with acute myeloid leukemia. The objectives this study were evaluate prognostic impact gene mutations and identify predictive genetic factors for treatment effect. Design Methods Data from mutation analyses NPM1 , CEBPA FLT3 MLL genes correlated 61 years treated within HD98B trial. Results frequencies were: 23%; 8.5% (analysis restricted normal karyotype); internal tandem duplications (ITD), 17%; tyrosine kinase domain mutations, 5%; partial duplications, 4.5%. genotype mutant was positively adverse cytogenetics as well higher white blood cell count negatively achievement complete remission. Cox regression analysis, significant interaction between without FLT3- ITD all- trans identified, beneficial effect on relapse-free overall survival subgroup patients. Other age, cytogenetics, logarithm count. Conclusions elderly leukemia, are associated remission, ‘mutant ITD’ appears be marker response all-trans given an adjunct (ClinicalTrials.gov Identifier: [NCT00151242][1]) . [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00151242&atom=%2Fhaematol%2F94%2F1%2F54.atom